Merck & Company Inc (MRK)vsOrganiGram Holdings Inc (OGI)
MRK
Merck & Company Inc
$145.39
-2.66%
HEALTHCARE · Cap: $365.34B
OGI
OrganiGram Holdings Inc
$1.00
-6.93%
HEALTHCARE · Cap: $153.70M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21431% more annual revenue ($66.57B vs $309.18M). OGI leads profitability with a 28.0% profit margin vs 4.8%. OGI trades at a lower P/E of 2.6x. OGI earns a higher WallStSmart Score of 60/100 (C).
MRK
Hold36
out of 100
Grade: F
OGI
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.5%
Fair Value
$83.26
Current Price
$145.39
$62.13 premium
Intrinsic value data unavailable for OGI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 49.4% year-over-year
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : OGI
The strongest argument for OGI centers on P/E Ratio, Price/Book, Revenue Growth. Profitability is solid with margins at 28.0% and operating margin at 5.0%. Revenue growth of 49.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : OGI
The primary concerns for OGI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while OGI is a growth play — different risk/reward profiles.
OGI carries more volatility with a beta of 1.91 — expect wider price swings.
OGI is growing revenue faster at 49.4% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
OGI scores higher overall (60/100 vs 36/100), backed by strong 28.0% margins and 49.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →OrganiGram Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?